These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18184439)

  • 41. MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
    Kuo SH; Wei MF; Lee YH; Lin JC; Yang WC; Yang SY; Huang CS
    Cell Oncol (Dordr); 2023 Oct; 46(5):1213-1234. PubMed ID: 37166744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
    Elledge RM; Clark GM; Chamness GC; Osborne CK
    J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
    Allred DC; Clark GM; Tandon AK; Molina R; Tormey DC; Osborne CK; Gilchrist KW; Mansour EG; Abeloff M; Eudey L
    J Clin Oncol; 1992 Apr; 10(4):599-605. PubMed ID: 1548522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.
    Schmitz KJ; Grabellus F; Callies R; Otterbach F; Wohlschlaeger J; Levkau B; Kimmig R; Schmid KW; Baba HA
    Breast Cancer Res; 2005; 7(2):R194-203. PubMed ID: 15743500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
    Sawaki M; Ito Y; Akiyama F; Tokudome N; Horii R; Mizunuma N; Takahashi S; Horikoshi N; Imai T; Nakao A; Kasumi F; Sakamoto G; Hatake K
    Breast Cancer; 2006; 13(2):172-8. PubMed ID: 16755113
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
    Spizzo G; Obrist P; Ensinger C; Theurl I; Dünser M; Ramoni A; Gunsilius E; Eibl G; Mikuz G; Gastl G
    Int J Cancer; 2002 Apr; 98(6):883-8. PubMed ID: 11948467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
    Curigliano G; Viale G; Bagnardi V; Fumagalli L; Locatelli M; Rotmensz N; Ghisini R; Colleoni M; Munzone E; Veronesi P; Zurrida S; Nolè F; Goldhirsch A
    J Clin Oncol; 2009 Dec; 27(34):5693-9. PubMed ID: 19884553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MYC amplification in subtypes of breast cancers in African American women.
    Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
    BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.
    Shukla S; Singh BK; Pathania OP; Jain M
    Indian J Med Res; 2016 May; 143(Supplement):S52-S58. PubMed ID: 27748278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a Meta-analysis].
    Guo H; Wei B; Zhang HY; Liu GJ; Bu H; Lang ZQ; Tang X; Dai QQ; Chen HJ; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2005 Mar; 34(3):140-6. PubMed ID: 15938823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
    Okutur K; Bassulu N; Dalar L; Aydin K; Bozkurt M; Pilanci KN; Dogusoy GB; Tecimer C; Mandel NM; Demir G
    Asian Pac J Cancer Prev; 2015; 16(7):2645-51. PubMed ID: 25854340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China.
    Xue C; Wang X; Peng R; Shi Y; Qin T; Liu D; Teng X; Wang S; Zhang L; Yuan Z
    Cancer Sci; 2012 Sep; 103(9):1679-87. PubMed ID: 22625227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.
    Badve S; Collins NR; Bhat-Nakshatri P; Turbin D; Leung S; Thorat M; Dunn SE; Geistlinger TR; Carroll JS; Brown M; Bose S; Teitell MA; Nakshatri H
    Am J Pathol; 2010 May; 176(5):2139-49. PubMed ID: 20228224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
    Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
    Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
    Peredo R; Sastre G; Serrano J; Hunter Mellado R
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
    Azim HA; Kassem L; Treilleux I; Wang Q; El Enein MA; Anis SE; Bachelot T
    Transl Oncol; 2016 Apr; 9(2):114-123. PubMed ID: 27084427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
    Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.
    Schmidt G; Meyberg-Solomayer G; Gerlinger C; Juhasz-Böss I; Herr D; Rody A; Liedtke C; Solomayer EF
    Arch Gynecol Obstet; 2014 Dec; 290(6):1221-9. PubMed ID: 25012601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.